ESOPJun 26, 2026, 04:08 PM
Aligos Stockholders Approve ESPP Amendment, Add 500,000 Shares
AI Summary
Aligos Therapeutics, Inc. held its Annual Meeting of Stockholders on June 25, 2026, where several proposals were approved. Key among these was an amendment to the 2020 Employee Stock Purchase Plan (ESPP), which reserves an additional 500,000 shares for issuance and eliminates the plan's "evergreen" provision for automatic share increases. Stockholders also re-elected two Class III directors, ratified the appointment of Ernst & Young LLP as independent auditors, and approved executive compensation on an advisory basis. The company will now hold advisory votes on executive compensation annually.
Key Highlights
- Stockholders approved an amendment to the 2020 Employee Stock Purchase Plan (ESPP).
- An additional 500,000 shares were reserved for issuance under the Amended ESPP.
- The ESPP's "evergreen" provision for automatic share increases was eliminated.
- Bridget Martell and Carole Nuechterlein were elected as Class III directors.
- Ernst & Young LLP was ratified as the independent auditor for 2026.
- Executive officer compensation was approved on an advisory basis.
- Future advisory votes on executive compensation will be held annually.
Price Impact
More from ALGS